Osakesijoittaminen

Optomed - Terveysteknologiayhtiö pörssiin

Optomedin AI-kumppani Eyenukilta vahvoja uusia tutkimustuloksia Eyeart-algoritminsa käytöstä.

13 tykkäystä

Optomedin valmistamalla Zeiss Visuscoutilla tuntuu olevan vauhtia myynnissä. Zeiss on tehnyt sopimuksen Rivoli Visionin kanssa, ilmeisesti Visuscoutia menee jokaiseen myymälään (ja niissä todnäk jokaiseen tutkimushuoneeseen). Arabeilla on varaa ostaa parasta. Niinhän se Kopsala mainitsi, että OEM-markkina vetää taas…

Rivoli Vision, the eyewear division of the Rivoli Group; one of the largest luxury watch and eyewear retailers in the GCC region, has announced their partnership with Zeiss, an internationally leading technology enterprise operating in the field of optics and optoelectronics for 175 years.
The strategic partnership will have Rivoli Vision use the sophisticated and technologically-advanced Zeiss products and services in all its eyewear concept stores through a 360 degree offering. This partnership will benefit the end-consumer through the state-of-the-art vision care equipment and expertise offered by Zeiss across Avanti, Rivoli EyeZone & Style 88 stores - setting apart Rivoli Vision from other eyewear retailers in the lower Gulf region.

Rivoli Vision operate Zeiss Vision Expert (ZVE) centres, Zeiss Vision Partner (ZVP) stores and are soon to launch the only Zeiss Vision Care (ZVC) centre in the region, which is at the apex of Zeiss’ vision care concepts and defined partner levels.
….
Rivoli Vision is today able to address such vision impairments through state-of-the-art Zeiss equipment such as Zeiss Visuscout 100, Zeiss i.Profiler Plus and Zeiss Visuplan 500 that help in pre-screening of general eye health to offer customers the opportunity of world class vision care coupled in a bespoke retail experience.
———

Myymälöitä on ilmeisesti n. 90 vuoden loppuun mennessä. Sitä en osaa äkkiseltään sanoa, tulevatko edellisessä artikkelissa mainitut vision care centret vielä myymälöiden päälle vaiko myymälöiden yhteydessä.

PS. Taiwanissa juhlistetaan Zeissin demorekalla Zeissin 175v päiviä, Visuscout on demorekassa paraatipaikalla.
https://www-prestigeonline-com.translate.goog/tw/people-events/events/德國蔡司175週年慶「光勢力」-品牌行動車檢測體驗/?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=fi&_x_tr_pto=nui

14 tykkäystä

Muikkarina, jos joku pääsee seuraamaan sessiota, olisi hienoa saada jonkinlainen rapsa palstalle.

5 tykkäystä

Kanadassa seulotaan Optomedilla.

Vision Loss Rehabilitation Canada (VLRC) is committed to ensuring equitable and accessible access to diabetic retinopathy screening – which is why we’re beginning to roll out a Diabetic Retinopathy Screening Program in ten communities across Ontario.

This innovative program, developed in partnership with community health organizations, features increased access points to screening, coordination, and vision rehabilitation for individuals with diabetic retinopathy. VLRC hopes to eventually expand the program to include communities across the country.
—-

15 tykkäystä

Vietnamista tuoreita kuulumisia, tutun näköinen kamerahan se kuvan vasemmassa laidassa pilkistää.

8 tykkäystä

Tänään Optomed mukana Nordean seminaarissa. Tapahtuma lienee vain Nordean varainhoidon asiakkaille. Jos joku pääsee mukaan, niin kuulumiset kiinnostaisi.

10 tykkäystä
6 tykkäystä

Noita CARnegien sisäisiä blokkeja menee lähes joka päivä. Joku isompi rahasto irtautuu pikkuhiljaa. Noiden Optomedin sijoittajatapahtumien yhteydessä blokkikoko tuppaa suurenemaan. Carnegien tapahtuman tienoilla nähtäneen jo isompaakin blokkia liikkeellä.

Dec 3 - Dec 3, 2021
CAR healthcare seminar

6 tykkäystä

Optomed järjestää webinaarin AI:n käytöstä retinopatian seulonnoissa. Vakuuttavaa kaartia mukana mm. Harvard Medical Schoolista.

Optomed Oyj : webinar on December 9, 2021

11/24/2021 | 08:20am EST

AI in eye screenings

Optomed warmly welcomes you to join the webinar on how to improve access to diabetic retinopathy screening with AI and handheld fundus cameras.

The webinar is free of charge and our honored key speaker of the event, Paolo S. Silva, MD, Assistant Chief of Telemedicine presents the benefits of using Artificial Intelligence (AI) in diabetic retinopathy screening.

In this webinar also the SELENA+ AI algorithm used in the Singapore national diabetic retinopathy screening program will be presented.

Save your place to the webinar and register here: Optomed – Webinar registration 2021 - Videopalvelin

Speakers

Paolo S. Silva, MD

Assistant Chief of Telemedicine, Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School

Dr. Paolo Silva is staff ophthalmologist and chief of telemedicine at the Beetham Eye Institute of the Joslin Diabetes Center. He is Assistant Professor of Ophthalmology at Harvard Medical School. His primary expertise lies in the fields of ocular telehealth for diabetic retinopathy, ultrawide field (UWF) retinal imaging and electronic medical record review. Dr. Silva has contributed 79 scientific publications with 26 original articles (17 as either first or last author), 16 study group publications, 25 review articles, 2 clinical guidelines and 9 book chapters. His work and efforts have been recognized with 20 national and international awards.

Petri Huhtinen, PhD

Clinical Director, Optomed

Petri has been working with preventive healthcare for the whole Millennium, which has made him a big fan of screening. He likes combining high-tech with human-touch to improve healthcare in general.

Petri manages Optomed’s clinical study portfolio making sure that clinical aspects remain in the core of company’s strategy. He also works closely with Optomed’s AI-partner network to ensure that Optomed’s customers have access to the best AI-solutions available. Petri holds PhD in in vitro diagnostics, MSc in biochemistry and BBA in Information systems science.

Ryan Tan

Executive, Business Development, EyRIS

Ryan works in the Business Development Team at one of the most innovative companies in Asia, EyRIS. His team has pioneered new business practices and developed new implementation techniques for Deep Learning Artificial Intelligence systems in both local and international markets. Over the course of his career in EyRIS, Ryan has overseen the deployment of SELENA+ in various regions namely Asia, Europe and Latin America. Today, he works with multiple customers, guiding them on their efforts to adopt Artificial Intelligence technology seamlessly and how they can benefit their patients more than ever before.

The event will be hosted by Laura Piila , Vice President Devices and Niina Huikuri , Vice President, Marketing from Optomed

Webinar agenda

14:00
Welcome

14:05
Retinopathy Screening Closer for All: Integrating Poinf of Care Artificial Intelligence
Paolo S. Silva, MD, Assistant Chief of Telemedicine, Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School

14:45
AI in Eye Screenings - Why should we care?
Petri Huhtinen, Clinical Director, Optomed

15:15
SELENA+: Artificial Intelligence as a diagnostic tool
Ryan Tan, Executive, Business Development, EyRIS

15:35
Closing

Register here: Optomed – Webinar registration 2021 - Videopalvelin

13 tykkäystä

Erittäin laaja katselmus AI:n käyttöönotosta UK:sta. Varpaillaan edetään, mutta eteenpäin mennään.

The UK NSC review concluded that further research is needed before implementing AI in the English DESP. The results from the review indicate that:
• some AI systems are accurate enough to do the initial reading of
images; 3 systems have been evaluated in good quality studies
conducted in the UK
• a system called iGradingM is implemented in Scotland and there is
evidence that its performance is good; however, we could not find
much evidence on the experience with its implementation and use
• there is some evidence that using the above AI systems for initial
screening of images provides better value for money, but the analyses
didn’t take into account some important factors
there is sufficient evidence from England that a system called EyeArt
v2.1 may be safe and provide better value for money; its
implementation should be investigated further
• the evidence on social and ethical aspects of using AI systems in
screening programmes should be assessed further.

3 tykkäystä

Optomedin kameran käytöstä hyviä kokemuksia dialyysihoidon yhteydessä. Retinopatian seulontakattavuus paranee tällä järjestelyllä merkittävästi.

By providing screening in renal units, it made attending annual diabetic eye screening easier for people on
haemodialysis
• We were also able to image 22 people who had previously failed to attend their screening appointments and 12
who had not attended in over 5 years
• Handheld imaging was essential for stretcher patients and could be further implemented to allow for screening
during haemodialysis as opposed to before and after

7 tykkäystä

Ehkä tässä olisi selkeyden vuoksi hyvä todeta, että EyeArt 1) ei ole Optomedin tuote 2) ei ole eksklusiivisesti Optomedin käytössä 3) on FDA hyväksytty Canonin laitteille jo 08/2020.

Näin on, eikä muuta ole missään väitettykään. Optomed käyttää käytännössä aina kumppanin algoiritmeja. AI-juna etenee myös UK:ssa, se pääpointtina.

Huomioihisi liittyen voi mainita sen, että Eyenuk on Optomedin jälleenmyyjä USA:ssa (AI referral käyttöön).

6 tykkäystä